These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1896809)

  • 21. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.
    Feutren G; Papoz L; Assan R; Vialettes B; Karsenty G; Vexiau P; Du Rostu H; Rodier M; Sirmai J; Lallemand A
    Lancet; 1986 Jul; 2(8499):119-24. PubMed ID: 2873396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.
    Campieri M; Ferguson A; Doe W; Persson T; Nilsson LG
    Gut; 1997 Aug; 41(2):209-14. PubMed ID: 9301500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
    Feagan BG; Sandborn WJ; Baker JP; Cominelli F; Sutherland LR; Elson CO; Salzberg BA; Archambault A; Bernstein CN; Lichtenstein GR; Heath PK; Cameron S; Hanauer SB
    Aliment Pharmacol Ther; 2005 Feb; 21(4):373-84. PubMed ID: 15709987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unsatisfactory effect of cyclosporin A treatment in Crohn's disease: a report of five cases.
    Löfberg R; Angelin B; Einarsson K; Gabrielsson N; Ost L
    J Intern Med; 1989 Sep; 226(3):157-61. PubMed ID: 2677208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclosporin A treatment in inflammatory bowel disease.
    Stange EF; Fleig WE; Rehklau E; Ditschuneit H
    Dig Dis Sci; 1989 Sep; 34(9):1387-92. PubMed ID: 2766906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
    Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levamisole in Crohn's disease: a randomized, double-blind, placebo-controlled clinical trial.
    Sachar DB; Rubin KP; Gumaste V
    Am J Gastroenterol; 1987 Jun; 82(6):536-9. PubMed ID: 3554991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.
    Feagan BG; Sandborn WJ; Lichtenstein G; Radford-Smith G; Patel J; Innes A
    Aliment Pharmacol Ther; 2006 Mar; 23(5):617-28. PubMed ID: 16480401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.
    Feagan BG; Rochon J; Fedorak RN; Irvine EJ; Wild G; Sutherland L; Steinhart AH; Greenberg GR; Gillies R; Hopkins M
    N Engl J Med; 1995 Feb; 332(5):292-7. PubMed ID: 7816064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease.
    Mansfield JC; Parkes M; Hawthorne AB; Forbes A; Probert CS; Perowne RC; Cooper A; Zeldis JB; Manning DC; Hawkey CJ
    Aliment Pharmacol Ther; 2007 Aug; 26(3):421-30. PubMed ID: 17635377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen.
    Prantera C; Kohn A; Mangiarotti R; Andreoli A; Luzi C
    Am J Gastroenterol; 1994 Apr; 89(4):513-8. PubMed ID: 8147352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial.
    Arora S; Katkov W; Cooley J; Kemp JA; Johnston DE; Schapiro RH; Podolsky D
    Hepatogastroenterology; 1999; 46(27):1724-9. PubMed ID: 10430331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective intravenous cyclosporin therapy in a patient with severe Crohn's disease on parenteral nutrition.
    Allam BF; Tillman JE; Thomson TJ; Crossling FT; Gilbert LM
    Gut; 1987 Sep; 28(9):1166-9. PubMed ID: 3119435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
    Sandborn WJ; Feagan BG; Radford-Smith G; Kovacs A; Enns R; Innes A; Patel J
    Gut; 2004 Oct; 53(10):1485-93. PubMed ID: 15361500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
    Cortot A; Colombel JF; Rutgeerts P; Lauritsen K; Malchow H; Hämling J; Winter T; Van Gossum A ; Persson T; Pettersson E
    Gut; 2001 Feb; 48(2):186-90. PubMed ID: 11156638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives.
    Landi B; Anh TN; Cortot A; Soule JC; Rene E; Gendre JP; Bories P; See A; Metman EH; Florent C
    Gastroenterology; 1992 May; 102(5):1647-53. PubMed ID: 1568574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Petryka R; Kuehbacher T; Hebuterne X; Roblin X; Klopocka M; Goldis A; Wisniewska-Jarosinska M; Baranovsky A; Sike R; Stoyanova K; Tasset C; Van der Aa A; Harrison P
    Lancet; 2017 Jan; 389(10066):266-275. PubMed ID: 27988142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
    Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.
    Feagan BG; McDonald JW; Rochon J; Laupacis A; Fedorak RN; Kinnear D; Saibil F; Groll A; Archambault A; Gillies R
    N Engl J Med; 1994 Jun; 330(26):1846-51. PubMed ID: 8196727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study.
    Suzuki Y; Motoya S; Takazoe M; Kosaka T; Date M; Nii M; Hibi T
    J Crohns Colitis; 2013 Apr; 7(3):239-47. PubMed ID: 22766525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.